Table 3.
The number and percentage of ERBB family mutations detected in the largest cancer studies listed on www.cbioportal.org (n = 3454). The cancer subsets selected for this analysis must have a frequency of ERBB family mutations over 12%.
| Study/cancer type | Number of mutations |
% of mutations |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| No. cases | No. HER WT/PIK3CA WT | No. PIK3CA Mut only | No. ERBB family Mut only | No. ERBB/PIK3CA dual mutants | % HER WT/ PIK3CA WT | % PIK3CA Mut only | % ERBB family Mut only | % ERBB/PIK3CA dual mutants | |
| Bladder urothelial carcinoma (TCGA)78 | 130 | 71 | 14 | 33 | 12 | 54.5 | 10.8 | 25.5 | 9.2 |
| Cervical squamous cell carcinoma and endocervical adenocarcinoma (TCGA) | 194 | 112 | 40 | 30 | 12 | 57.8 | 20.8 | 15.2 | 6.2 |
| Colorectal adenocarcinoma (DFCI)79 | 619 | 359 | 92 | 130 | 38 | 58.0 | 14.9 | 21.0 | 6.1 |
| Esophageal carcinoma (TCGA) | 185 | 128 | 16 | 38 | 3 | 69.3 | 8.4 | 20.7 | 1.6 |
| Head and neck squamous cell carcinoma (TCGA)80 | 279 | 179 | 48 | 41 | 11 | 64.3 | 17.1 | 14.7 | 3.9 |
| Pan-lung cancer (TCGA)81 | 1144 | 781 | 75 | 271 | 17 | 68.3 | 6.5 | 23.7 | 1.5 |
| Stomach adenocarcinoma (TCGA)82 | 289 | 133 | 34 | 98 | 24 | 46.0 | 11.7 | 34.0 | 8.3 |
| Skin cutaneous melanoma (TCGA) | 366 | 254 | 5 | 101 | 6 | 69.3 | 1.4 | 27.7 | 1.6 |
| Uterine corpus endometrioid carcinoma (TCGA)83 | 248 | 69 | 103 | 47 | 28 | 28.0 | 41.7 | 19.0 | 11.3 |
Mut, mutation; WT, wild type.